Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 63(23): 14502-14521, 2020 12 10.
Artigo em Inglês | MEDLINE | ID: mdl-33054196

RESUMO

We describe the design of a novel PDE4 scaffold and the exploration of the dual-soft concept to reduce systemic side effects via rapid elimination: introducing ester functionalities that can be inactivated in blood as well as by the liver (dual-soft) while being stable in human skin. Compound 40 was selected as a clinical candidate as it was potent and rapidly degraded by blood and liver to inactive metabolites and because in preclinical studies it showed high exposure at the target organ: the skin. Preclinical and clinical data are presented confirming the value of the dual-soft concept in reducing systemic exposure.


Assuntos
Dermatite Atópica/tratamento farmacológico , Inibidores da Fosfodiesterase 4/farmacologia , Animais , Descoberta de Drogas , Humanos , Inibidores da Fosfodiesterase 4/uso terapêutico
2.
J Med Chem ; 48(17): 5412-4, 2005 Aug 25.
Artigo em Inglês | MEDLINE | ID: mdl-16107139

RESUMO

The known KDR inhibitor SU5416 and several analogues of the indolin-2-one family were surprisingly found to be highly efficacious in the EAE model, an established model for multiple sclerosis. The high in vivo effect could be correlated to in vitro inhibition of the pro-inflammatory cytokine IL-2. Activity following po administration was obtained with several analogues and via the use of prodrugs.


Assuntos
Encefalomielite Autoimune Experimental/metabolismo , Indóis/síntese química , Esclerose Múltipla/metabolismo , Animais , Encefalomielite Autoimune Experimental/tratamento farmacológico , Técnicas In Vitro , Indóis/química , Indóis/farmacologia , Interleucina-2/antagonistas & inibidores , Interleucina-2/biossíntese , Leucócitos Mononucleares/efeitos dos fármacos , Leucócitos Mononucleares/metabolismo , Camundongos , Esclerose Múltipla/tratamento farmacológico , Relação Estrutura-Atividade , Receptor 2 de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores
3.
J Med Chem ; 48(7): 2667-77, 2005 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-15801857

RESUMO

This paper describes how the introduction of "cationic" aliphatic amino groups in the chalcone scaffold results in potent antibacterial compounds. It is shown that the most favorable position for the aliphatic amino group is the 2-position of the B-ring, in particular in combination with a lipophilic substituent in the 5-position of the B-ring. We demonstrate that the compounds act by unselective disruption of cell membranes. Introduction of an additional aliphatic amino group in the A-ring results in compounds that are selective for bacterial membranes combined with a high antibacterial activity against both Gram-positive and -negative pathogens. The most potent compound in this study (78) has an MIC value of 2 muM against methicillin resistant Staphylococus aureus.


Assuntos
Antibacterianos/síntese química , Chalconas/síntese química , Compostos de Amônio Quaternário/síntese química , Antibacterianos/química , Antibacterianos/farmacologia , Cátions , Chalconas/química , Chalconas/farmacologia , Contagem de Colônia Microbiana , Desenho de Fármacos , Hemólise/efeitos dos fármacos , Humanos , Técnicas In Vitro , Cinética , Resistência a Meticilina , Testes de Sensibilidade Microbiana , Compostos de Amônio Quaternário/química , Compostos de Amônio Quaternário/farmacologia , Staphylococcus aureus/efeitos dos fármacos , Relação Estrutura-Atividade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA